This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Moleculin Biotech’s 8K filing here.
About Moleculin Biotech
Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.
Featured Articles
- Five stocks we like better than Moleculin Biotech
- Find and Profitably Trade Stocks at 52-Week Lows
- The Great CPU Race: AMD and Intel Battle for Dominance
- Investing in Construction Stocks
- GameStop Turns a Profit: So What? It’s Still Not Worth Investing
- Airline Stocks – Top Airline Stocks to Buy Now
- C3.ai Stock Surges on Strong Sales Despite Profit Concerns
